This website has been developed by Besins Healthcare (UK) Ltd.

This website has separate sections for healthcare professionals (containing promotional information), and patients who have been prescribed Testogel® (testosterone) 16.2 mg/g gel, within the UK.

Please confirm that:

This website is provided for HCPs in the UK by Besins Healthcare (UK) Ltd.

Why Testogel® 16.2 mg/g gel?

Why Testogel



Kaufman et al evaluated the efficacy of titrated doses of Testogel® 16.2 mg/g gel in 274 testosterone deficient men* who applied the gel daily for 182 days.1


  • Following titration, significantly more subjects receiving active treatment (range 81.6% to 82.5%) had testosterone values within the eugonadal range compared with placebo (range 28.6% to 37.0%) on all study days (p< 0.0001)


  • A similar percentage of serious treatment-emergent adverse events (TEAEs) occurred in the Testogel® 16.2 mg/g gel (2.1%) and placebo groups (2.5%)

*Inclusion criteria: 18 to 80 years of age; Morning total testosterone < 10.4 nmol/L; Body Mass Index: 18 kg/m2 to 40 kg/m2

Testogel® 16.2 mg/g gel restores testosterone levels to within the normal range

Efficacy graph

Adapted from Kaufman JM, et al.1


Quality of life

The time required for testosterone therapy (TTh) to improve symptoms of testosterone deficiency (TD) varies (dependent on the organ/process that is affected) but positive effects start within just 3–4 weeks and can start to have an impact on the day-to-day lives of patients. Such effects include (vs. baseline): 2,3

  • Increased muscle mass
  • Decreased fat mass
  • Decreased waist circumference
  • Increased exercise capacity
  • Increased erectile function
  • Increased morning erections
  • Increased sexual activity/ejaculations
  • Increased sexual interest and desire
  • Increased satisfaction with sex life

For further details regarding the efficacy time frames associated with alleviation of symptoms refer to time to symptom improvement.



  1. Kaufman JM, Miller MG, Garwin JL, et al. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men. J Sex Med. 2011;8(7):2079–2089.
  2. Hackett G, Kirby M, Edwards D, et al. UK policy statements on testosterone deficiency. Int J Clin Pract. 2017;71(3–4).
  3. Saad F, Aversa A, Isidori AM, et al. Onset of effects of testosterone treatment and time span until maximum effects are achieved. Eur J Endocrinol. 2011;165(5):675–685.

TES/2020/009. April 2021.

Adverse event reporting

Adverse events should be reported. Reporting forms and information can be found at or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Besins Healthcare (UK) Ltd Drug Safety on 0203 862 0920 or Email: